Quality of life · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in physical signs (Severity of impairment) Measured by the VRMC scale (higher is better) · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
1 finding from 1 review
Diagnosis of PTSD after treatment · various
It is very uncertain whether any early psychological intervention changes PTSD diagnosis: post‐treatment compared with waiting list/usual care (very low certainty).
1 finding from 1 review
Depressive symptoms · various
1 finding from 1 review
Anxiety · various
1 finding from 1 review
General functioning ‐ not measured · various
1 finding from 1 review
PTSD diagnosis · various
Any early psychological intervention may leads to lower PTSD diagnosis: 3–6 months compared with waiting list/usual care (low certainty).
2 findings from 1 review
Dropout · various
Any early psychological intervention showed no clear difference in dropouts from treatment compared with waiting list/usual care (low certainty).
1 finding from 1 review
Severity of PTSD symptoms · various
1 finding from 1 review
Depressive symptoms · various
1 finding from 1 review
Anxiety · various
1 finding from 1 review
Dropout · various
Any early psychological intervention may leads to higher dropouts from treatment compared with active control condition (low certainty).
1 finding from 1 review
Severity of PTSD symptoms · various
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review